سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Jannati Yazadan Abad, Mahdi, Allahyari, Abolghasem, Kamandi, Mostafa, Arasteh, Omid, Varmaghani, Mehdi, Karbasforooshan, Hedyieh, Jaafari, Mahmoud Reza, Kheradmand, Hamidreza, Eftekhari, Abolfazl, Elyasi, Sepideh. (1404). Evaluation of nano-curcumin oral formulation efficacy in prevention of chemotherapy-induced adverse reactions in metastatic colorectal cancer patients. , 16(2), 148-161. doi: 10.22038/ajp.2025.26317
Mahdi Jannati Yazadan Abad; Abolghasem Allahyari; Mostafa Kamandi; Omid Arasteh; Mehdi Varmaghani; Hedyieh Karbasforooshan; Mahmoud Reza Jaafari; Hamidreza Kheradmand; Abolfazl Eftekhari; Sepideh Elyasi. "Evaluation of nano-curcumin oral formulation efficacy in prevention of chemotherapy-induced adverse reactions in metastatic colorectal cancer patients". , 16, 2, 1404, 148-161. doi: 10.22038/ajp.2025.26317
Jannati Yazadan Abad, Mahdi, Allahyari, Abolghasem, Kamandi, Mostafa, Arasteh, Omid, Varmaghani, Mehdi, Karbasforooshan, Hedyieh, Jaafari, Mahmoud Reza, Kheradmand, Hamidreza, Eftekhari, Abolfazl, Elyasi, Sepideh. (1404). 'Evaluation of nano-curcumin oral formulation efficacy in prevention of chemotherapy-induced adverse reactions in metastatic colorectal cancer patients', , 16(2), pp. 148-161. doi: 10.22038/ajp.2025.26317
Jannati Yazadan Abad, Mahdi, Allahyari, Abolghasem, Kamandi, Mostafa, Arasteh, Omid, Varmaghani, Mehdi, Karbasforooshan, Hedyieh, Jaafari, Mahmoud Reza, Kheradmand, Hamidreza, Eftekhari, Abolfazl, Elyasi, Sepideh. Evaluation of nano-curcumin oral formulation efficacy in prevention of chemotherapy-induced adverse reactions in metastatic colorectal cancer patients. , 1404; 16(2): 148-161. doi: 10.22038/ajp.2025.26317

Evaluation of nano-curcumin oral formulation efficacy in prevention of chemotherapy-induced adverse reactions in metastatic colorectal cancer patients

Avicenna Journal of Phytomedicine
دوره 16، شماره 2، خرداد و تیر 2026، صفحه 148-161    اصل مقاله (1.1 M)
نوع مقاله: Original Research Article
شناسه دیجیتال (DOI): 10.22038/ajp.2025.26317
نویسندگان
Mahdi Jannati Yazadan Abad1؛ Abolghasem Allahyari2؛ Mostafa Kamandi2؛ Omid Arasteh1؛ Mehdi Varmaghani3؛ Hedyieh Karbasforooshan1؛ Mahmoud Reza Jaafari4؛ Hamidreza Kheradmand5؛ Abolfazl Eftekhari6؛ Sepideh Elyasi* 7
1Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
2Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Management Sciences and Health Economics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
4Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
5Mashhad University of Medical Sciences, School of Medicine, Mashhad, Iran
6Babol University of Medical Sciences, School of Medicine, Babol, Iran
7Pharmacotherapy
چکیده
Objective: The aim of the present study is to evaluate the effectiveness of oral formulation of nano-curcumin in prevention of some chemotherapy-induced adverse reactions.
Materials and Methods: In this study, 84 patients with metastatic colorectal cancer were randomly assigned into the nano-curcumin (40 mg capsule) or placebo groups, receiving treatments three times daily, beginning the first day to the end of the sixth cycle of chemotherapy. To investigate various adverse events, including hematologic adverse reactions, diarrhea, hand-foot syndrome (HFS) and neuropathy, the criteria of National Cancer Institute Common Terminology for Adverse Events (NCI-CTCAE) version 5 were implemented after the third and sixth course.
Results: The CTCAE peripheral neuropathy score was significantly different between the two groups at the end of the 6th course (p=0.029) but not the third course (p=0.157). No significant response was observed for neutropenia, anemia, thrombocytopenia, HFS, or diarrhea at the end of both third (P=0.267, 0.258, 0.933, 0.377, and 0.811, respectively) and 6th courses (p=0.456, 0.645, 0.772, 0.34, and 0.114, respectively).
Conclusion: Nano-curcumin in dose of 40 mg thrice daily was not effective in prevention of neuropathy, HFS and hematologic adverse reactions induced by XELOX/FOLFOX-6 regimens. Further research with larger sample size on different nano-curcumin dosing schedules is suggested.


کلیدواژه‌ها
Metastatic colorectal cancer Nanocurcumin؛ Chemotherapy toxicity؛ Cancer progression؛ FOLFOX/XELOX±Bevacizumab
آمار
تعداد مشاهده مقاله: 314
تعداد دریافت فایل اصل مقاله: 503